New drug duo aims to outsmart advanced kidney cancer

NCT ID NCT05928806

Terminated Disease control Sponsor: Michael B. Atkins, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial is testing a new combination of two immunotherapy drugs, botensilimab and balstilimab, against the standard combination of ipilimumab and nivolumab for people with advanced kidney cancer that has spread. The study plans to enroll 120 patients who have not had prior treatment. The goal is to see if the new combo shrinks tumors more effectively and for a longer time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Botensilimab and balstilimab (immunotherapy drugs)
What this could lead to: If successful, this could offer a new, possibly more effective immunotherapy option for people with advanced kidney cancer.
What could go wrong: This is a Phase 2 trial, so it's still early. The new combo may not work better than the standard treatment, and it could have serious side effects like immune system attacks on healthy organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED RENAL CELL CARCINOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Columbia University Irving Medical Center

New York, New York, 10032, United States
Cornell University

Ithaca, New York, 14850, United States
Dana-Farber - Partners Cancer Care, Inc

Boston, Massachusetts, 02215, United States
Georgetown University

Washington D.C., District of Columbia, 20057, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Indianapolis, Indiana, 46202, United States
John Theurer Cancer Center

Hackensack, New Jersey, 07601, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Penn Medicine Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States
University of California San Diego

La Jolla, California, 92093, United States
University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States
Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322, United States
Yale University, Yale Cancer Center

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.